Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: A study of pharmacokinetic and psychological risk factors

doi:10.1007/s10072-022-06485-y

Published November 7, 2022 | Version v1

Journal article Open

Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: A study of pharmacokinetic and psychological risk factors

Manuela Contin et al.¹

1. IRCCS Istituto delle Scienze Neurologiche di Bologna

Raw data for the article titled "Screening for impulse control disorders in Parkinson’s disease and dopamine agonist use: A study of pharmacokinetic and psychological risk factors"

Files

Files (98.2 kB)

Name	Size	Download all
Data base DCI-DA-PD_Zen.xlsx md5:e4473fe72d51bd6fcecdbebbebc65619	98.2 kB	Download

Views

Downloads

Show more details

	All versions	This version
Views	64	64
Downloads	20	20
Data volume	2.0 MB	2.0 MB

More info on how stats are collected....

DOI

Resource type

Journal article

Publisher

Zenodo

Published in

Neurological sciences, 2022.

Technical metadata

Created: November 7, 2022
Modified: November 8, 2022

Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: A study of pharmacokinetic and psychological risk factors

Creators

Description

Files

Files (98.2 kB)